Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Spastic Cerebral Palsy.~* Chronic pain, related to spastic muscle. Chronic pain defined as: 1)Recurring regional pain for at least three months AND 2)Pain intensity on average for the last 24 hours ≥3 on Numerical Rating Scale.~* Signed Informed consent.~Exclusion Criteria:~* Allergy/hypersensitivity to Dysport® or any of its components.~* Pregnancy.~* Women who breastfeed their children.~* Treatment with Botulinum toxin-A within the last five months.~* If there has been dose changes in any muscle-tone altering medication within two weeks of Visit 1.~* A clear degenerative cause behind the pain as elucidated by the clinical examination (e.g. history of osteoarthritis).~* Intellectual disability and/or communication impairment that disable the individual from answering the questionnaires and giving informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botulinum toxin-A (Dysport®) (Type: ACTIVE_COMPARATOR): Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
- Normal saline (Type: PLACEBO_COMPARATOR): Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain

Based on this trial design, predict the completion outcome and termination type (if applicable).